Cartesian Therapeutics Announces Positive Phase 2b Results for mRNA CAR-T Therapy Descartes-08 in Myasthenia Gravis and Raises $130 Million

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Please feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

mRNACell Therapy Biotechnology CompanyCartesian TherapeuticsCartesian Therapeutics, Inc. said that its leading research drug helps patients with autoimmune diseases and has attracted the attention of many biopharmaceutical companies in recent years.

This Maryland-based biotechnology company recently entered into a partnership withSelecta BiosciencesThe reverse merger and listing, the company said, its experimental therapyDescartes-08In Neurocommunication Disorders: Myasthenia Gravis2bReached the primary endpoint in the study. It helped71% The patient in60 Achieved in the scoring system5 Points or greater improvement. In contrast, patients receiving placebo showed25%, the patient,pThe value is0.018，CartesianSaid on Tuesday morning.

The researchers studied26The company plans to meet with U.S. regulators by the end of the year for the second-phase meeting, based on patient data.

A few days ago, Johnson & Johnson stated that it will2024Submit its own myasthenia gravis drug by the end of the yearnipocalimabGet approval because it hopes to emulateargenx, AstraZeneca andUCB. Several other biopharmaceutical companies are seeking to enter the field, including Amgen,Immunovant、Biohaven、Dianthusetc.

Cartesian TherapeuticsIs one of the various cell therapy biotechnology companies joining the emerging autoimmune field. This biotechnology company believes that itsmRNA CAR-TTargeted therapy may have advantages because it does not require lymphocyte-depleting chemotherapy and can be administered in an outpatient setting.

Chief Executive OfficerCarsten Brunn"In a press release, they stated: 'We believe that the positive data announced today demonstrates our newmRNAClinical concept validation of the platform, and highlightedDescartes-08ForMGThe potential for patients to achieve deep and lasting improvements.

At the same time,Cartesian Therapeuticsstated that it has begun in systemic lupus erythematosus (SLE) Patients receiving the same cellular therapy2Phase research. It also passes throughPIPE Raised1.3 Billion USD, fromHBM Healthcare Investments、Invus、Schooner Capital、Surveyor Capital and renowned researcher and entrepreneurTim Springer etc.

Cartesian TherapeuticsThe stock price$RNACDropped by about in pre-market trading on Tuesday before the opening.11%。

In addition,Cartesian TherapeuticsAlso appointed Kemal Malik (Kemal Malik) as a board member. This former Bayer executive is also a British investor and incubatorSynconaThe board members.

Source: https://endpts.com/